Deal facts
- Buyer
- Cytek Biosciences, Inc.
- Target
- Luminex Corporation
- Deal value
- USD 46,500,000
- Announced
- 13 February 2023
- Status
- Completed
- Sector
- Healthcare
- Country
- United States
- Consideration
- cash
Sources
Deal timeline
1 update- CompletedClosed
Cytek Biosciences, Inc. completes acquisition of Luminex Corporation
Item 2.01 Completion of Acquisition or Disposition of Assets As previously disclosed in the Current Report on Form 8-K filed by Cytek Biosciences, Inc. (the “Company”) on February 13, 2023, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Luminex Corporation (“Luminex”), pursuant to which the Company acquired certain assets relating to the flow cytometry and ima
Source
For business owners
What would selling your own business involve?
Use the deal as a starting point, not a valuation benchmark. Learn the decisions behind a sale and apply them to your own preparation.
Guides are free to read. Free tools require email access; indicative results are not professional advice.
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
Circle Health Holdings Limited to acquire CHC Healthcare Holdings Limited
Circle Health Holdings Limited has agreed to acquire CHC Healthcare Holdings Limited in a strategic acquisition within the healthcare sector. Both entities are based in…
- Buyer
- Circle Health Holdings Limited
- Target
- CHC Healthcare Holdings Limited
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
BioAdaptives, Inc. to acquire Xycota Biosciences LLC
BioAdaptives, Inc. entered into a definitive Membership Interest Purchase Agreement on October 29, 2026 to acquire 100% of the issued and outstanding membership interest…
- Buyer
- BioAdaptives, Inc.
- Target
- Xycota Biosciences LLC
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Ayrmid Ltd. to acquire Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. and its subsidiary KPT Texas LLC filed voluntary Chapter 11 petitions on November 2, 2026 in the U.S. Bankruptcy Court for the Southern Dist…
- Buyer
- Ayrmid Ltd.
- Target
- Karyopharm Therapeutics Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Azenta, Inc. to acquire SynPlexity Inc.
Azenta, Inc. acquired SynPlexity Inc. on October 28, 2026, by entering into a Stock Purchase Agreement with SynPlexity, its stockholders and other parties. Under the agr…
- Buyer
- Azenta, Inc.
- Target
- SynPlexity Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Pelthos Therapeutics Inc. to acquire Castle Creek Biosciences, Inc.
Pelthos Therapeutics Inc. signed an Agreement and Plan of Merger on October 30, 2026 to acquire Castle Creek Biosciences, Inc., according to Pelthos's Form 8-K of that d…
- Buyer
- Pelthos Therapeutics Inc.
- Target
- Castle Creek Biosciences, Inc.
- Deal value
- Not disclosed
- Deal type
- strategic acquisition
Buyer history
Cytek Biosciences, Inc.
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive